HC Wainwright Comments on Bolt Biotherapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:BOLT)

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Research analysts at HC Wainwright upped their Q3 2024 earnings per share (EPS) estimates for shares of Bolt Biotherapeutics in a report issued on Wednesday, August 14th. HC Wainwright analyst E. White now expects that the company will post earnings of ($0.38) per share for the quarter, up from their previous estimate of ($0.43). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q4 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.55) EPS, FY2025 earnings at ($0.91) EPS and FY2026 earnings at ($0.71) EPS.

Other analysts also recently issued research reports about the company. SVB Leerink reiterated a “market perform” rating and set a $1.00 price target (down previously from $3.00) on shares of Bolt Biotherapeutics in a research note on Wednesday, May 15th. Stifel Nicolaus reaffirmed a “hold” rating and set a $1.50 target price (down previously from $6.00) on shares of Bolt Biotherapeutics in a research report on Wednesday, May 15th. Leerink Partnrs downgraded Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 14th. Finally, Guggenheim restated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, May 15th. Five analysts have rated the stock with a hold rating, According to MarketBeat, the company has an average rating of “Hold” and an average target price of $3.50.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ:BOLT opened at $0.69 on Friday. The company has a current ratio of 5.68, a quick ratio of 5.68 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $26.46 million, a PE ratio of -0.42 and a beta of 0.94. Bolt Biotherapeutics has a 1 year low of $0.65 and a 1 year high of $1.56. The firm has a fifty day moving average price of $0.73 and a 200 day moving average price of $0.98.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.08). The business had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.19 million. Bolt Biotherapeutics had a negative return on equity of 51.74% and a negative net margin of 556.59%.

Hedge Funds Weigh In On Bolt Biotherapeutics

An institutional investor recently bought a new position in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. purchased a new position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned 0.09% of Bolt Biotherapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.